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Behavioral impairments are the most empirical consequence of diabetes mellitus
documented in both humans and animal models, but the underlying causes are still
poorly understood. As the cerebellum plays a major role in coordination and execution of
the motor functions, we investigated the possible involvement of glial activation, cellular
degeneration and glutamate transportation in the cerebellum of rats, rendered diabetic by
a single injection of streptozotocin (STZ; 45mg/kg body weight; intraperitoneally). Motor
function alterations were studied using Rotarod test (motor coordination) and grip strength
(muscle activity) at 2nd, 4th, 6th, 8th, 10th, and 12th week post-diabetic confirmation.
Scenario of glial (astroglia and microglia) activation, cell death and glutamate transportation
was gaged using immunohistochemistry, histological study and image analysis. Cellular
degeneration was clearly demarcated in the diabetic cerebellum. Glial cells were showing
sequential and marked activation following diabetes in terms of both morphology and cell
number. Bergmann glial cells were hypertrophied and distorted. Active caspase-3 positive
apoptotic cells were profoundly present in all three cerebellar layers. Reduced co-labeling
of GLT-1 and GFAP revealed the altered glutamate transportation in cerebellum following
diabetes. These results, exclusively derived from histology, immunohistochemistry and
cellular quantification, provide first insight over the associative reciprocity between
the glial activation, cellular degeneration and reduced glutamate transportation, which
presumably lead to the behavioral alterations following STZ-induced diabetes.
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INTRODUCTION
Diabetes mellitus is a metabolic disorder well known for its
austere impact on central nervous system. Cognitive and behav-
ioral dysfunctions are being the most apparent CNS impair-
ments reported in both humans (Petrofsky et al., 2005; Kodl and
Seaquist, 2008) and animal models of diabetes (Biessels et al.,
1994; Coleman et al., 2004; Guven et al., 2009). It is held that
altered metabolism of lipids, proteins and carbohydrates follow-
ing diabetes leads to oxidative stress and cell death in the brain,
causing a state of dysfunctions in cognition and behavior. Patients
with diabetes and hyperglycemia present poor motor coordina-
tion and reducedmotor activity (Daneman, 2001; Cox et al., 2005;
Petrofsky et al., 2005).
Cerebellum is involved in the control and execution of sev-
eral aspects of motor functions, including coordination (Horne
and Butler, 1995), muscle tone (Manto, 2010) and locomotion
(Morton and Bastian, 2004). The cerebellar circuitry involves a
distinctive single layer of Purkinje cells (PC) as the sole output
neurons that receive input directly or indirectly from the climbing
fibers and parallel mossy fibers. The precise input/output sys-
tem of inhibitory and excitatory synaptic information enables
the Purkinje cells to predominantly control and coordinate
the cerebellar motor functions. Bergmann glia (radial form
of astroglia), elaborately wrap the dendritic spines and exci-
tatory synapses of Purkinje neurons and actively take part in
the processing and maintenance of excitatory synaptic informa-
tion via glutamate transporters (Rothstein et al., 1994; Bellamy,
2006). Compelling evidence indicated that astroglial cells pos-
sess high affinity glutamate transporters (GLT-1/GLAST) and
are notably involved in maintaining the extracellular glutamate
concentration at sub-excitotoxic levels via uptaking the excess
of glutamate and thus prevent possible neuronal cell death due
to glutamate toxicity (Rothstein et al., 1996; Anderson and
Swanson, 2000). Furthermore, impairment in glutamate trans-
porter GLT-1/GLAST were related to the neurodegenerative dis-
orders like epilepsy, hypoxia/ ischemia, amyotrophic lateral scle-
rosis, Alzheimer’s disease (AD), Parkinson disease (PD) and
schizophrenia (Sims and Robinson, 1999; Danbolt, 2001).
Glia (astroglia and microglia) have a wide range of functions
in CNS ranging from the regulation of innate immunity, scav-
enging dead cell debris, scaffolding and protecting neurons to the
regulation and maintenance of synaptic transmission and puta-
tive integration of information with neurons. Following any brain
insult or immune breaching, glial cells get activated and exhibit
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morphological transformations from resting to activated, increase
in their cell population and secrete an array of inflammatory
molecules (Patro et al., 2005; Luo and Chen, 2012; Boche et al.,
2013). Glial activation based on the progression of insult and
severity of stimulus, imposes both beneficial (Morgan et al., 2004;
Luo and Chen, 2012) and detrimental effects (Heneka et al., 2010)
upon the brain cells.
So far, only a couple of studies have elucidated the alter-
ations in cellular mechanisms of cerebellum following diabetes
(Hernández-Fonseca et al., 2009; Antony et al., 2010). However, to
best of our knowledge, consequences were rarely correlated with
the behavioral alterations that too with limitations. The potential
effects of diabetes on the cerebellum are still poorly understood.
Therefore, present study was aimed to investigate the influence
and scenario of glial activation, cellular degeneration and glu-
tamate transportation in cerebellum and associated behavioral
patterns of the experimentally induced diabetic rats.
MATERIALS AND METHODS
ANIMALS
All experiments were carried out using 3 month old male Wistar
rats weighing 200–220 gm (School of Studies in Neuroscience,
Jiwaji University, Gwalior), as their susceptibility to STZ-induced
diabetes is previously well reported (McNeill, 1999). The care and
maintenance of animals was carried out as per the guidelines of
CPCSEA and all the experimental procedures were pre-approved
by Institutional Animal Ethics Committee, Jiwaji University,
Gwalior (India). The rats were housed in polypropylene cages
having clean dust free husk with ad libitum access to food and
water. Animals were maintained in controlled environment hav-
ing temperature of 25 ± 2◦C and 50–65% humidity with a fixed
12:12 h light dark cycle.
INDUCTION OF DIABETES
Type 1 diabetes was induced by a single intraperitoneal injection
of 45mg/kg body weight of Streptozotocin (STZ; Sigma) prepared
in 0.1M citrate buffer (pH = 4; Stevens et al., 2007; Lebed et al.,
2008; Nagayach et al., 2014) to the overnight fasted rats. Control
rats were injected with vehicle alone. Diabetes was confirmed at
72 h post STZ injection, by testing the blood glucose level (non-
fasting) through tail snipping method using AccuChek Sensor
Comfort (Roche Diagnostics, Berlin, Germany) and the animals
having blood glucose level of 250mg/dl or above were considered
as diabetic. Animal’s blood glucose level (non-fasting) and body
weight were checked once a week upto 12 weeks to ensure the dia-
betic stature. Diabetic rats were randomly divided into following
groups, i.e., 2nd, 4th, 6th, 8th, 10th,and 12th week post-diabetic
confirmation. Subsequently animal’s food and water consump-
tion were also measured daily to further confirm the diabetic
symptoms like polyphagia and polydipsia.
BEHAVIORAL TEST
All the animals (n = 6/group) were subjected to behavioral test.
Behavioral assessment for motor coordination and neuromuscu-
lar strength was achieved by rotarod test and grip strength meter
respectively. The animals were subjected to the behavioral test on
the aforementioned days of diabetic duration.
ROTAROD TEST
Rotarod test was performed as per previously described method
(Kumar et al., 2013) with the help of Rotamex 5 (Columbus
Instruments, USA). Animals were acclimatized for three consec-
utive days at start speed of 2 rpm and a maximum speed of 8 rpm
for 100 s of duration. After 24 h of acclimatization, final reading
was taken with acceleration time of 2 rpm (start speed) to 40 rpm
(final speed) for 420 s as total time duration. An animal fall was
detected by infrared photo-cells automatically with the help of
software (Rotamex 5, Columbus Instruments, USA). Once the
photocells lose the detection of the animal, the falling latency of
that animal was recorded by the software attached with the appa-
ratus. Falling latency is directly proportional to the riding time.
Test animals were given 3 trials each with a resting time interval
of 15min each between the successive trials. Final trials were per-
formed four times for each animal in every group, and the values
were computed for single mean value for every animal. The exper-
imental room conditions (light and temperature) and timing were
consistent in all the trials.
GRIP STRENGTH
Grip strength meter (Columbus Instruments, USA) was used to
detect the motor/ muscular function of the diabetic animal. The
apparatus is consisted of a force gage digital display (sensor range:
0–5 kg) connected with specially designed forelimb grasping pull
bar assemblies (76 × 50mm) made up of steel wire. The values
of grip strength were recorded automatically via RS-232 interface
connected to the computer and a software Grip strength version
1.19. The test animal was placed carefully over the metallic grid
and allowed to hold the grid through its forelimbs. Proper care
was taken for applying gentle uniform force while animal was
pulled back by holding the tail until its grip gets released. The
maximum strength value animal takes to release the grid was dis-
played on the screen and was saved for further data analysis. Six
trials were performed successively followed by 2min resting inter-
val, for each animal in every group and the values were computed
for single mean value for every animal. The experimental room
conditions (light and temperature) and timing were consistent in
all the trials.
TISSUE COLLECTION AND PROCESSING
Animals from both control and diabetic groups were sacrificed at
the aforementioned time points, i.e., 2nd, 4th, 6th, 8th, 10th and
12th week. Under ether anesthesia perfusion was performed as
per previously described methods (Patro et al., 2010b; Nagayach
et al., 2014). Animals were perfused via transcardiac puncture,
with 2% paraformaldehyde prepared in 0.01M phosphate buffer
(PB) after flushing with phosphate-buffered saline (PBS; 0.01M;
pH 7.4). After perfusion-fixation the brain was dissected out care-
fully, weighed and post-fixed in the same fixative overnight at
4◦C. The tissues were then cryoprotected in Phosphate buffered-
Sucrose gradients, i.e., 10, 20, and 30% at 4◦C until tissue settled
at the bottom. After processing the sagittal sections of cerebel-
lum were cut serially using Microm HM 525 (Thermo Scientific)
cryostat, at a thickness of 14μm. The sections were collected on
chrom alum-gelatin coated slides and stored at −20◦C till they
were used for immunohistochemical studies.
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IMMUNOHISTOCHEMISTRY
Immunostaining was performed as per previously described
methods (Patro et al., 2009; Nagayach et al., 2014). Briefly, cry-
ocut sections were sequentially treated with 1% Triton X-100 and
1% hydrogen peroxide in washing buffer for 30min each at room
temperature followed by three washings (5min each) with buffer.
Non-specific proteins were blocked with 1% normal serum (dis-
solved in washing buffer) of same species as secondary antibody,
for 90min in a humid chamber. Following blocking, the sections
were incubated with primary antibodies, GFAP (1:2000, Rabbit
polyclonal, Dako, Denmark), Iba-1 (1:1500, Rabbit polyclonal,
Wako Japan), Active caspase-3 (1:1000, Rabbit polyclonal, R&D
Systems), at the specified titre overnight at 4◦C. Next day, the sec-
tions were then incubated with appropriate secondary antibody
anti-rabbit biotin-labeled (1:100, Sigma) for 90min at room tem-
perature. After three buffer washings (5min each), sections were
further incubated with streptavidin-biotin-peroxidase complex
(1:200, Amersham) for 90min at room temperature. Subsequent
to buffer wash the color was developed with chromogen solution
containing 3, 3′-diaminobenzidine tetrahydrochloride (0.025%)
and hydrogen peroxide (0.006%) dissolved in the buffer for
20min at room temperature. Nickel enhancement was done for
caspase-3 labeling. Later on trailed by distilled water wash, slides
were dried at 37◦C, dehydrated in 100% alcohol, cleared in xylene,
and mounted with DPX for further microscopic evaluations.
CO-IMMUNOLABELING
The co-immunolabeling was done as per previously described
method (Patro et al., 2010b). Followed by permeablization with
0.5% Triton X-100 and non-specific protein blocking with 5%
normal serum (dissolved in washing buffer), sections were incu-
bated with cocktail of primary antibodies GFAP (1: 2000; Rabbit
polyclonal, Dako, Denmark) and GLT-1 (1: 1000; Guinea pig
polyclonal, Chemicon) for overnight at 4◦C to label the astroglia
and glutamate transporters respectively. Next day, the sections
were washed with PBS buffer and incubated with the cock-
tail of flurochrome conjugated secondary antibody Cy3 (1:300;
anti-guinea pig, Vector) and Fluorescein isothiocynate (FITC;
1:400; anti-rabbit, Abcam) for the visualization of GLT-1 and
GFAP respectively. Afterwards, sections were washed with PBS
buffer for four times (10min each) to remove the excess of sec-
ondary antibody and mounted with antifade VECTASHIELD®
HardSet™ mounting medium with DAPI (Vector Laboratories,
Burlingame, CA).
To ensure comparable immunostaining, sections were pro-
cessed together at the same time in the same conditions. Omission
of primary antibodies served as negative control.
Assessment of morphologic alterations and quantification of
the expression level of various proteins was achieved with quan-
titative immunohistochemical analysis simultaneously on the
similar platform in the brain section. Furthermore, phenotypic
assessment also provided concrete information about the spe-
cific cyto- and/or histo-morphological change, which is mostly
required in explaining the glial activation and allied subcellular
and vascular deformations. Undoubtedly Western blot analysis
would have been more useful but could not be performed due
to limitations of animal use.
HISTOLOGICAL STUDY
For histological study a separate set of animals from each group
were perfused and processed for paraffin sectioning as per pre-
viously described method (Kumar et al., 2013). Briefly, after
perfusion-fixation, tissues were thoroughly washed with water
and dehydrated with graded series of ethyl alcohol. Then, the tis-
sues were cleared in toluene and infiltrated in Paraplast (Sigma,
m. p. 56–58◦C) for proper impregnation of wax. Tissue blocks
were made in paraffin and serial sagittal sections of cerebel-
lum were cut at a thickness of 6μm using Leica RM2135
microtome.
To observe the histological changes, tissue sections were
stained with 0.1% cresyl violet acetate (Sigma certified stain, C-
5042), prepared in acetate buffer (pH 3.5) and routinely used
Delafield’s Haematoxylin and eosin stain.
IMAGE ANALYSIS
Bright field images were captured by using Leica DM 6000 micro-
scope equipped with Leica DFC 310 FX digital camera and Leica
Application Suite (LAS V4.2) software in order to have magnified
images showing fine structural details for more demarcated mor-
phological analysis. Fluorescent co-immunolabeled sections were
visualized using a Leica DM 6000 microscope with digital camera
(Leica DFC 310 FX) operating with the Leica Application Suite
Advanced Fluorescence (LAS AF, Leica) and images were grabbed
using I3 and N2.1 filters for FITC and Cy3 respectively and over-
laid with the overlay module of Leica Application Suite Advanced
Fluorescence.
CELL QUANTIFICATION AND ANALYSIS
Cell quantification was done on the sections stained through stan-
dard HRP-conjugated immunohistochemistry method. The cell
population was estimated in all the ten folias of the cerebellum.
The cerebellar regions for quantification were delineated as three
frames per folia in the two sections per animal in all the groups.
Tissue sections corresponding to the region of interest were
included in the quantification ensuring the equivalence in the
procedure. In order to count equal areas (mm2) in every sub-
ject, a 23,299.6μm2 frame comprising exclusively the anatom-
ical areas of interest was applied to ensure that counts were
representative of the analyzed areas. Photomicrographs of the
regions were photographed with Leica Laborlux microscope fit-
ted with digital camera (Leica DFC 420 DC). Cell counting
was performed on the digital pictures with Leica Qwin soft-
ware (Version 3.1) application interactive measure (IM) and
presented as the total number of cells/mm2. The area fraction
was measured with NIH ImageJ software (http://rsb.info.nih.
gov/ij/download.html).
STATISTICAL ANALYSIS
Results were statistically analyzed with SigmaStat software 3.5
version and were reported as mean ± s.e.m. In experiments,
unpaired t-test was used to assess the significance between the
two groups, and withmore than two groups, assessment was done
by One-Way ANOVA followed by the Tukey’s post-hoc test. The
threshold for statistical significance was set at p ≤ 0.05. In figures
∗p ≤ 0.01, ∗∗p ≤ 0.001.
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FIGURE 1 | Blood glucose level (A) and body weight (B) of control and
STZ-induced diabetic animals. Diabetic animals were showing
significantly reduced body weight and increased blood glucose level in
comparison to controls. Values are presented as mean ± s.e.m. (n = 6.8).
∗∗p ≤ 0.001 for comparison of diabetic group with the respective controls.
RESULTS
STZ INDUCTION RESULTED IN CHARACTERISTIC DIABETES
All the STZ-induced animals exhibited characteristic signs of dia-
betes as their blood glucose level was significantly high in 2nd
week [t(14) = −12.165, p ≤ 0.001], 4th week [t(14) = −20.013,
p ≤ 0.001], 6th week [t(14) = −18.467, p ≤ 0.001], 8th week
[t(14) = −11.689, p ≤ 0.001], 10th week [t(10) = −14.964, p ≤
0.001] and 12th week [t(10) = −16.339, p ≤ 0.001] time points
of diabetes as compared to controls (Figure 1A). Similarly, the
food consumption and water intake also increased in the dia-
betic animals presenting symptoms of polyphagia and polydipsia.
Body weight was found to be significantly reduced in 2nd week
[t(14) = 5.692, p ≤ 0.001], 4th week [t(14) = 5.439, p ≤ 0.001],
6th week [t(14) = 5.959, p ≤ 0.001], 8th week [t(14) = 5.963,
p ≤ 0.001], 10th week [t(10) = 3.762, p ≤ 0.001] and 12th week
[t(10) = 3.729, p ≤ 0.001] in diabetic animals upto the 12th weeks
(Figure 1B).
BEHAVIORAL ASSESSMENT
Rotarod test
Motor coordination was assessed as total length of time spent
by the animals on the rotating rod. The falling latency of dia-
betic animals was significantly decreased in 2nd week [t(10) =
4.865, p ≤ 0.001], 4th week [t(10) = 8.22, p ≤ 0.001], 6th week
FIGURE 2 | Alteration in motor functions following STZ-induced
diabetes. (A) On rotarod performance diabetic animals presented
significantly reduced motor coordination on accelerating rod in comparison
to controls. (B) Grip strength assessment data showed significantly weak
grip strength of diabetic animals in comparison to controls. Values are
presented as mean ± s.e.m. (n = 6). ∗∗p ≤ 0.001 for comparison of diabetic
group with the respective controls.
[t(10) = 6.531, p ≤ 0.001], 8th week [t(10) = 4.526, p ≤ 0.001],
10th week [t(10) = 6.085, p ≤ 0.001] and 12th week [t(10) =
8.575, p ≤ 0.001] of diabetic time points as compared to the
respective controls (Figure 2A).
Grip strength
A significant reduction was observed in the grip strength of all
the diabetic animals and the values were significant at all the time
points studied, i.e., 2nd week [t(10) = 4.885, p ≤ 0.001], 4th week
[t(10) = 4.658, p ≤ 0.001], 6th week [t(10) = 5.970, p ≤ 0.001],
8th week [t(10) = 4.641, p ≤ 0.001], 10th week [t(10) = 4.926,
p ≤ 0.001] and 12th week [t(10) = 4.339, p ≤ 0.001] as compared
to the respective controls (Figure 2B) indicating a reducedmuscle
strength following STZ-induced diabetes.
Effect of diabetes on glial cells
GFAP expression. An increased GFAP expression in the dia-
betic cerebellum upto 12th week of diabetes was immunohisto-
chemically observed. In controls, the GFAP labeled Bergmann
glial fibers were presenting intact, thin and erect morphology
(Figure 3A) while in diabetic animals Bergmann glial fibers
became hypertrophied, fragmented and disorganized at all the
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FIGURE 3 | Effect of diabetes on Bergmann glial fibers (BGF). GFAP immunolabeled Bergmann glial fibers (BGF) of cerebellumwere presenting a disorganized
and hypertrophied morphology (B–G) at all the diabetic time points in comparison to controls having thin, intact and erect morphology (A). Scale bar = 50μm.
time points (Figures 3B–G). Similarly, the astroglia in the white
matter and granule cell layer also presented activated mor-
phology having thick, dense and fragmented processes with
the darkly stained cell body as compared to resting astroglia
with thin processes and lightly stained cell body in controls
(Figure 4). Quantitation of GFAP positive cells showed a sig-
nificant gradual increment (p ≤ 0.001) in astroglia population
at all the diabetic points, i.e., 2nd week [F(11,359) = 18.548,
p ≤ 0.001], 4th week [F(11,359) = 24.187, p ≤ 0.001], 6th week
[F(11,359) = 23.972, p ≤ 0.001], 8th week [F(11,359) = 31.600,
p ≤ 0.001], 10th week [F(11,359) = 33.203, p ≤ 0.001] and 12th
week [F(11,359) = 33.246, p ≤ 0.001] as compared to the respec-
tive controls. A progressive escalation was also observed in the
cerebellar astroglial population following diabetes (Figure 4i).
Volumetric fraction (area fraction) assessment also showed a
significant increment in the percentage of GFAP expression
at all the diabetic points, i.e., 2nd week [F(11,359) = 9.292,
p ≤ 0.001], 4th week [F(11,359) = 8.904, p ≤ 0.001], 6th week
[F(11,359) = 9.714, p ≤ 0.001], 8th week [F(11,359) = 13.042, p ≤
0.001], 10th week [F(11,359) = 16.788, p ≤ 0.001] and 12th week
[F(11,359) = 19.489, p ≤ 0.001] as compared to the respective
controls (Figure 4ii).
Microglial activation. STZ-induced diabetes resulted in intense
microglial activation and morphological transformation to acti-
vated phenotype in the cerebellum as shown by Iba-1 immunola-
beling. In controls, microglia were seen with resting morphology
having small, thin, multiple processes and round small cell body
(Figure 5A). Following diabetes, an increase in Iba-1 expres-
sion was clearly evident in the cerebellar microglia. With the
advancing diabetic duration, the resting microglia got trans-
formed into activated microglia exhibiting thick and fewer num-
bers of processes with darkly stained Iba-1 positive irregular cell
body (Figures 5B–G). Additionally, there was also a significant
increase in microglial population in the diabetic rat cerebellum
at all the time point studied, i.e., 2nd week [F(11,359) = 9.533,
p ≤ 0.001], 4th week [F(11,359) = 11.995, p ≤ 0.001], 6th week
[F(11,359) = 13.822, p ≤ 0.001], 8th week [F(11,359) = 15.490,
p ≤ 0.001], 10th week [F(11,359) = 17.953, p ≤ 0.001) and 12th
week [F(11,359) = 16.285, p ≤ 0.001] as compared to the respec-
tive controls indicating microgliosis in response to the alterations
following diabetes (Figure 5i). Percentage of Iba-1 expression as
area fraction is also increasing at 2nd week [F(11,359) = 4.682,
p = 0.044], 4th week [F(11,359) = 5.817, p = 0.002], 6th week
[F(11,359) = 6.084, p = 0.001], 8th week [F(11,359) = 7.145, p ≤
0.001], 10th week [F(11,359) = 8.352, p ≤ 0.001], and 12th week
[F(11,359) = 6.845, p ≤ 0.001] of diabetic cerebellum as compared
to the controls (Figure 5ii).
Cell death following diabetes
A reflective cell death in cerebellum following STZ-induced dia-
betes upto 12 weeks was observed from active caspase-3 immuno-
labeling. Active caspase-3 positive cells were clearly evident in
molecular layer, Purkinje cell layer and granule cell layer of
the diabetic cerebellum in comparison to controls (Figure 6).
Interestingly, active caspase-3 expression was more prominent
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FIGURE 4 | Persistent astroglial activation following diabetes. GFAP
immunolabeled light microscopic images of both diabetic and control
cerebellum depicting profound astroglial activation during diabetes. Astroglial
activation was consistent in white matter and in all the three layers of the
cerebellum upto the 12th week of diabetic duration bearing thick, dense, wavy
and fragmented processes with a darkly stained large cell body (B–G; arrows).
In controls astroglia were presenting resting morphology having thin, fine
processes and lightly stained small cell body (A; arrowheads). ML, Molecular
layer; PCL, Purkinje cell layer; GCL, Granule cell layer; WM,White matter. Scale
bar = 50μm. Quantitation and area fraction graphs were showing a
significantly increased population (i) and volumetric fraction (ii) of GFAP + cells
in the diabetic cerebellum upto the 12 weeks post-diabetic confirmation in
comparison to controls. Same alphabets on bars indicate non-significant
differences between groups at the given time points (p ≤ 0.001). Value
represents mean ± s.e.m. of the 30 readings/ animal/ time point. ∗∗p ≤ 0.001
for comparison of diabetic group with the respective controls.
in the nuclei of Purkinje cells and in surrounding Bergmann
glial cell bodies in comparison to the molecular and granule cell
layer. The inclination in Purkinje and Bergmann cell degenera-
tion was constant at all the diabetic time points in comparison
to controls. Quantitatively, caspase-3 positive cells were signif-
icantly increasing with advancing diabetic state, i.e., 2nd week
[F(11,359) = 17.409, p ≤ 0.001], 4th week [F(11,359) = 22.529,
p ≤ 0.001], 6th week [F(11,359) = 23.258, p ≤ 0.001], 8th week
[F(11,359) = 22.187, p ≤ 0.001], 10th week [F(11,359) = 23.848,
p ≤ 0.001], and 12th week [F(11,359) = 28.146, p ≤ 0.001] as
compared to the respective controls (Figure 6i) suggesting a
severe cellular degeneration in the cerebellar tissue. Percentage
of area fraction of caspase-3 expression was also showing the
similar trend. The increment of caspase-3 expression was con-
sistent at all the diabetic time points, i.e., 2nd week [F(11,359) =
16.397, p ≤ 0.001], 4th week [F(11,359) = 22.076, p ≤ 0.001],
6th week [F(11,359) = 23.570, p ≤ 0.001], 8th week [F(11,359) =
22.544, p ≤ 0.001], 10th week [F(11,359) = 22.569, p ≤ 0.001],
and 12th week [F(11,359) = 24.413, p ≤ 0.001] as compared to the
controls (Figure 6ii).
Cellular degeneration following STZ-induced diabetes
Histological staining with cresyl violet depicted a marked cellu-
lar degeneration in cerebellum following diabetes. Nissl bodies in
control cerebellar cells were darkly stained with populous density.
While following STZ-induced diabetes, a consistent loss of Nissl
substance in cerebellar cells upto the 12th week was observed.
Additionally, the effect of diabetes was more demarcated and
regular in Purkinje cells in terms of both morphological alter-
ations and cell number. In controls, darkly stained Purkinje cells
were uniformly aligned presenting centralized nuclei (Figure 7A),
while in diabetic cerebellum a marked Purkinje cell degenera-
tion was observed with disorganized Purkinje cell layer devoid of
nucleus and condensed lightly stained Nissl substance in cell body
signifying abrupt accumulation of rough endoplasmic reticulum
(RER; Figures 7B–G). With advancing diabetic state voids were
also observed in the monolayer of Purkinje cells indicating the
persistent Purkinje cell loss in cerebellum.
Histoarchitectural changes in the cerebellum during diabetes
Cerebellum of control rats stained with haematoxylin and eosin
showed intact arrangement of molecular, Purkinje and granu-
lar cell layers with normal distribution of glial cells (Figure 8A).
Purkinje cell monolayer was continuous with a centrally placed
nucleus in the cell body. STZ-induced diabetic rats also showed
intact arrangement of all the three layers. In contrast to control
most of the Purkinje cells of the diabetic cerebellum were swollen,
showing chromatolysis and vacuolation, suggesting necrotic cell
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FIGURE 5 | Microglial activation followed with morphological
transformation during diabetes. Iba-1 immunohistochemical analysis of
STZ-induced diabetic and control animals revealed the gradual microglial
activation in the cerebellum of the diabetic animal upto 12 weeks (B–G)with
having thick and reduced processes and irregular darkly stained cell body.While
in controls (A) themicrogliawere in resting phasewith thin andmore number of
processes and round cell body. Insets were showing the magnified images of
Iba-1 expressing cells exhibiting the resting (A) and activated (B–G)morphology
in cerebellum.Scale bar=50μm.Cell quantitation (i) and area fraction (ii) graphs
were showing the diabetes associated elevation in the number of microglia and
volumetric fraction from 2nd week onwards in comparison to controls. The
increment in microglia population is indicative of proliferation following
diabetes in cerebellum. Same alphabets on bars indicate non-significant
differences between groups at the given time points (p ≤ 0.001). Value
represents mean ± s.e.m. of the 30 readings/ animal/ time point. ∗p ≤ 0.01,
∗∗p ≤ 0.001 for comparison of diabetic group with the respective controls.
death. This focal area of necrosis was surrounded by activated glial
cells depicting the typical histomorphology of neuronophagia
(Figures 8B–G). In addition, some Purkinje neurons presented
shrunken and pyknotic appearance suggestive of apoptotic cell
death (Figures 8B–G). Severity and incidence of dying or degen-
erating cerebellar cells increased with the advancing stage of dia-
betes. Activation of astroglia and microglia was evident from 2nd
week and remained consistent till 12 week of the diabetic rat cere-
bellum. In the later stages activated, glial cells were circumscribing
the necrotic/apoptotic neurons (Figures 8C–G). Interestingly, a
discontinuity in the Purkinje cells monolayer indicates a corre-
lation with the severity of degenerative histoarchitectural alter-
ations following diabetes. Details of histopathological findings are
presented, in the summary incidence table (Table 1).
Effect of diabetes on astroglial glutamate transporter
On the assessment of GLT-1 transporters presence on astroglia
and BGF, we recorded a reduced co-immunolabeling of glutamate
transporters on both astroglia (Figure 9) and BGF (Figure 10)
following diabetes in cerebellum in all the diabetic time points.
While in controls, GLT-1 marker was noticeably co-labeled with
GFAP expressing astroglia and BGF. Quantitation of GLT-1 +
GFAP co-labeled cells also showed a significant reduction in the
GLT-1 co-labeling with GFAP immunoexpression upto the 12th
week of diabetes confirmation, i.e., 2nd week [F(11,359) = 5.705,
p = 0.003], 4th week [F(11,359) = 5.560, p = 0.005], 6th week
[F(11,359) = 5.850, p = 0.002], 8th week [F(11,359) = 6.452, p ≤
0.001], 10th week [F(11,359) = 7.883, p ≤ 0.001], and 12th week
[F(11,359) = 7.904, p ≤ 0.001] as compared to their respective
controls (Figure 11). Thus, reduced expression of GLT-1 co-
labeled GFAP+ Bergmann glial fibers and astroglial cells (white
matter and granule cell layer) in the diabetic cerebellum indi-
cates the altered glutamate transportation in the cerebellum as a
detrimental effect of increased blood-glucose level.
DISCUSSION
Diabetes involves various comorbid complications such as learn-
ing and memory impairment (Biessels et al., 1996; Popoviç et al.,
2001), reduced muscular strength (Andersen et al., 2005), behav-
ioral deficits (Sweetnam et al., 2012) and more. The causative
factors for these alterations range from structural, cellular to
neurochemical changes leading to direct neuronal damage and
thus loss of information processing (Thorré et al., 1997; Alvarez
et al., 2009). STZ-induced animal model is widely used to elu-
cidate the diabetes associated complications. The studies related
to cognition and behavior following diabetes is limited to the
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FIGURE 6 | Cell death detection in diabetic cerebellum. Active caspase-3
Immunolabeling revealed the conspicuous cell death following diabetes in
cerebellum. Apoptotic cells were clearly visible in all the three layers of the
diabetic cerebellum at all the time points (B–G). While in controls the labeling
was negligible (A). The effect of diabeteswas clearly demarcated in the Purkinje
cell layer as Bergmann glial cells (B–G; red arrows) surrounding Purkinje cells
(B–G; red arrowheads) were also showing intense immunolabeling of active
caspase-3 in comparison to the molecular and granule cell layer of cerebellum.
Insets were showing the enlarged images of apoptotic Purkinje cell with
surroundedBergmannglial cells. Scalebar=50μm.Cell quantitation (i) andarea
fraction (ii) graphs were presenting the increased stature of active caspase-3
immunolabeled apoptotic cells in various layers of the cerebellum following
diabetes. Quantitative assessment data were showing significant increment in
apoptotic cell population and volumetric fraction at all the diabetic time points in
comparison to controls. Same alphabets on bars indicate non-significant
differences between groups at the given time points (p ≤ 0.001). Value
representsmean± s.e.m. of the 30 readings/animal/time point. ∗∗p ≤ 0.001 for
comparison of diabetic group with the respective controls.
hippocampal atrophy and allied cellular changes. A sole study
reported the role of cerebellar alterations in behavioral deficits
following hypoglycaemia in terms of decreased GABA receptor
and CREB expression (Sherin et al., 2010). Cerebellum is asso-
ciated with emotion, cognition and behavior (Rapoport et al.,
2000; Schmahmann and Caplan, 2006) and alterations to the
cerebellum lead to motor deficits, dementia, schizophrenia and
other psychiatric disorders (Baldaçara et al., 2008; Sui and Zhang,
2012). In the present study, we have demonstrated the influence
of glial activation, cell death, and loss of glutamate transporters in
the diabetic rat cerebellum on reduced motor and muscle activity.
The STZ-induced rats presented the characteristic signs of
diabetes as regular body weight loss and subsequent high blood-
glucose level due to the loss of pancreatic beta cells as has been
reported earlier (Junod et al., 1969). During diabetes, the glu-
cose utilization in the brain gets decreased (McCall, 1992), which
makes the brain more vulnerable to the critical pathological
events. A significant cellular degeneration and/or cell loss was
observed in the cerebellum of STZ-induced diabetic animals in
both immunohistochemical and histological study consistently
upto the 12th week of diabetic duration. Active caspase-3 pos-
itive cells and were successively increasing in all the layers of
the cerebellum. The cellular degeneration of both Purkinje and
Bergmann glial cells in the cerebellum indicates the compro-
mised motor information processing following diabetes as they
both together constitute the unit of synaptic information trans-
mission (Bellamy, 2006). The deleterious effect of diabetes and
hyperglycemia as cell death was previously well reported with
underlying mechanisms of activation of p53 transcription fac-
tor, intrinsic cell death pathway and decreased IGF-I level due
to increased blood glucose (Yamaguchi et al., 2001; Muranyi
et al., 2003; Lechuga-Sancho et al., 2006). Studies suggested that
p53 transcription factor is involved in the activation of caspase-
3, 9, and 6 (Culmsee and Mattson, 2005) and also takes part
in some forms of cerebellar cell death (Inamura et al., 2000).
Similarly increased blood-glucose level as observed in this study
is expected to reduce the IGF-I level in cerebellar granule neurons
(Linseman et al., 2002). Constitutively, the reduced IGF-I level
due to high blood-glucose level or activation of p53 transcription
factors or intrinsic cell death pathwaymight be the potential cause
behind the sequential apoptotic cell death following diabetes in
the cerebellum as reported in this study.
Glial cells are susceptible to any change or disruption in the
brain. In response to adverse state, glial cells transform their
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FIGURE 7 | Cellular degeneration in cerebellum following diabetes.
Histological cresyl violet (CV) staining depicted cellular degeneration in
cerebellum in terms of lightly stained condensed nissl substance, loss of
nucleus and reduced number of Purkinje cells (B–G; red arrows) following
STZ-induced diabetes upto the 12 week. The degenerated purkinje cells were
clearly demarcated in all the diabetic time points (red arrows). Additionally,
cells in molecular and granule cell layer were reduced in number with small
lightly stained cell bodies presenting chromatolysis following diabetes (B–G;
black arrows) in comparison to the controls having darkly stained large sized
cells (A; black arrowhead). In controls, Purkinje cells were darkly stained
arranged in a uniform monolayer with centric nuclei (A; red arrowheads).
Scale bar = 50μm.
morphology and proliferate to combat the baleful condition
(Patro et al., 2005; Verkhratsky et al., 2012). In the current study,
following diabetic condition astroglia and microglia were also
showing alterations in terms of their activated morphology and
increased population upto the 12th week of diabetes in the cere-
bellum. This activation might be a customized approach to mod-
ulate the effect of excessive cell death following diabetes. However,
our present astroglial observations in the diabetic cerebellum are
differed from the previous studies revealing the decrement in
astrocyte GFAP levels in the cerebellum both in terms of cell num-
ber and labeling intensity (Coleman et al., 2004; Guven et al.,
2009) at 4/8th weeks of diabetic duration. As astroglia play, a
compelling role in transporting glucose and its metabolites to
neurons, thus alterations in glucose level following diabetes might
be a possible reason of astroglial dystrophy in the cerebellum.
Microglial activation and proliferation following diabetes in
the cerebellum was previously well reported following diabetic
retinopathy (Zeng et al., 2000), acute cerebral infarction in pres-
ence of diabetes mellitus (Li et al., 2011) and in diabetic hyper-
algesic rat spinal cord (Daulhac et al., 2006). Similar microglial
activation and increment in population was also observed in
the present study of cerebellum following STZ-induced diabetes.
Our previous studies showed that being the prime immune cell
in brain, microglia gets readily activated in response to any
injury (Saxena et al., 2007; Patro et al., 2010b), inflammation
(Patro et al., 2010a, 2013) and metabolic disorder (Nagayach
et al., 2014). During immune breaching or cell death, microglia
becomes activated to protect and repair the damaged tissue via
removing the dying cell debris and facilitating the healing process
(Hanisch and Kettenmann, 2007; Kettenmann et al., 2011). On
the contrary, microglial activation is also responsible in aggra-
vating the neurodegeneration (Block and Hong, 2005; Venero
et al., 2011). Therefore, microglia activation following diabetes
in the cerebellum as shown in this study might be in response
of cell death for providing the potential damage control or pos-
sibly microglial activation was itself inducing the cell death via
generating various immune mediators.
Astroglia actively participates in the synaptic transmission
related to the modulation of synaptic information processing
via astroglial glutamate transporters forming tripartite synapse
(Araque et al., 1999; Santello et al., 2012). On neuron-glia, synap-
tic junction glutamate transporters help in regulating the level of
extracellular glutamate and minimize the glutamate excitoxicity.
Likewise in cerebellum, Bergmann glial cells possess glutamate
transporters (GLAST/GLT-1), that not only help in glutamate
uptake (Rothstein et al., 1994; Bellamy, 2006) but also remove
the excess of glutamate from the synaptic cleft and act as sig-
nal transducer (López-Bayghen et al., 2007). In cerebellum unlike
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FIGURE 8 | Histoarchitectural alterations in cerebellum during
diabetes. Hematoxylin and eosin stained diabetic cerebellum presented a
marked degeneration and cell death consistently upto the 12th week.
Control cerebellar tissue presented intact cerebellar layers having normal
Purkinje cells with dendrites and centrally placed nuclei (A; red thin
arrow) and resting astroglia (A; blue thin arrow) and microglia (A; green
thin arrow). Effect of diabetes was clearly evident in cerebellar cells
presenting pathological signs of degeneration and cell death (B–G). 2nd
week onwards Purkinje cells were presenting chromatolysis,
necrosis/apoptosis (B–G; red and orange thick arrows), pyknosis (B–G;
red thick arrows), vacuolation (G; dotted green circle) and neuronophagia
(E,F; dotted yellow circle). Astroglia (B–G; thick blue arrow) and microglia
(B–G; thick green arrow) activation was also observed in cerebellar layers
at all the diabetic time points. Scale bar = 50μm.
Table 1 | Summary incidence table of lesions in control and STZ-induced diabetic rat cerebellum.
Control 2nd week 4th week 6th week 8th week 10th week 12th week
Ballooning of purkinje cell − ++ ++ ++ ++ ++ ++
Chromatolysis − ++ ++ + + + + + ++ + + ++ + + ++
Vacuolation − − ++ ++ + + + + + + + + ++
Necrosis/Apoptosis − ++ ++ + + + + + + + + ++ + + ++
Pyknosis/Dark purkinje cell − ++ ++ + + + + + + + + ++ + + ++
Gliosis − + ++ ++ + + + + + ++ + + ++
Neuronophagia − − ++ ++ + + + + + ++ + + ++
−, Nil (less than 5%); +, minimal (5–10%); ++, mild (10–20%); + + +, moderate (20–30%); + + ++, severe (more than 30%).
GLAST, GLT-1 is relatively low in density but it plays a similar
and imperative role in uptaking of glutamate (Takayasu et al.,
2009). In this study we observed that with advancing diabetic state
glutamate transporters, i.e., GLT-1 were reducing on astroglia
and Bergmann glial fibers. Reduction in GLT-1 mRNA level
is well reported in various brain disorders like ischemia, amy-
otrophic lateral sclerosis, Alzheimer’s disease and Huntington’s
disease (Torp et al., 1995; Sims and Robinson, 1999; Gegelashvili
et al., 2001) with subsequent consequences of secondary neu-
ronal cell death, excessive activation of glutamate receptors,
abnormal neuronal activity and ensuing excitotoxic degeneration
(Rothstein et al., 1996; Tanaka et al., 1997). As the present results
markedly showed the hypertrophied activated astroglia and frag-
mented processes of Bergmann glial fiber, which is possibly due
to the degeneration of Bergmann glial cell bodies, and the gluta-
mate transporters are localized on the processes of astroglia and
BGF, so it might be possible that fragmentation of astroglia and
BGF processes were causing the loss of glutamate transporters
and commencing the glutamate excitotoxicity in the cerebellum.
Another possibility for selective loss of GLT-1 on astrocytes was
due to the diabetes associated oxidative stress as it causes the
oxidation of glutamate transporters (Trotti et al., 1998).
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FIGURE 9 | Diabetes caused reduction in astroglial glutamate transporter
GLT-1. Co-immunolabeling of GFAP + GLT-1 showing a marked reduction in
astroglial glutamate transporters following diabetes in cerebellum. The GLT-1
was clearly localized with the processes of GFAP expressing astroglia in
controls tissue of cerebellum. Insets were showing the enlarged co-labeled
(GLT-1 and GFAP) image of astroglia (A). Scale bar = 100μm.
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FIGURE 10 | Effect of diabetes on the glutamate transporters of the BGL. Following STZ-induced diabetes the GLT-1 expression was reduced in Bergmann
glial fibers in comparison to controls consistently in all the diabetic time points. Scale bar = 100μm.
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FIGURE 11 | Quantification of co-labeled cells (GLT-1 + GFAP) in
various layers of the cerebellum following diabetes. There is significant
reduction in the population of co-labeled cells at all the diabetic time points
as compared to their respective controls. Same alphabets on bars indicate
non-significant differences between groups at the given time points
(p ≤ 0.001). Value represents mean ± s.e.m. of the 30 readings/ animal/
time point.∗p ≤ 0.01, ∗∗p ≤ 0.001 for comparison of diabetic group with the
respective controls.
Purkinje cell as the prime relay neurons of the cerebellum
plays an imperious role in motor coordination and learning. As
reported earlier the inevitable loss of Purkinje cell resulted in var-
ious motor disorders including autism, ataxia and Huntington’s
disease (Whitney et al., 2008; Matilla-Dueñas et al., 2012; Rüb
et al., 2013). Consistent with our immunohistochemical cell death
study, histological data also depicted the specific Purkinje cell
degeneration and cell loss in cerebellum extending the aura of
cellular alterations following diabetes. The loss of Purkinje cell
might be explained as an effect of altered cerebellar microenvi-
ronment due to increased blood-glucose level and glial activation.
Possibly, the degeneration of cerebellar cells and allied alterations
in communication elements (Purkinje neuron, glia, glutamate
transporters, etc.) are instigating the alterations in the motor
information processing in the cerebellum.
Alterations in motor behavior following diabetes was previ-
ously well reported both in human and animal models with
underlying causes of increased blood glucose level associated
micro- ormacrovascular complications (Demirbüken et al., 2012)
and altered neurotransmission (Sherin et al., 2012). In our study,
the diabetic animals were showing reduced falling latency on
Rotarod and poor or weak muscular strength in grip strength
meter indicating impaired motor/muscle activity upto the 12
weeks of diabetic duration. Cerebellum participates in the con-
trol and coordination of motor/muscle activity, which is possibly
controlled and maintained by the neuron-glia shuttle. In the
cerebellum, the main interceptive unit of motor control, i.e.,
Purkinje neurons are surrounded by the Bergmann cell bod-
ies, and its dendritic synapses are enwrapped by the Bergmann
glial fibers expressing GLT-1 on its surface membrane (Rothstein
et al., 1994; Chaudhry et al., 1995). Thereby, it was suggested
that excitatory synapses of Purkinje neurons and associated cere-
bellar motor control are regulated by the glia-neuron circuitry
via glutamate transporters present in BGF (Bellamy and Ogden,
2005). A study also suggested that the Bergmann glia as an
FIGURE 12 | Schematic representation showing possible occurrence of
events in cerebellum following STZ-induced diabetes. Diabetes
simultaneously induce glial activation, cellular degeneration and glutamate
toxicity in cerebellum and the subsequent triangular associative interplay
between these three factors resulted in motor deficits following diabetes.
astrocyte in molecular and Purkinje layer of the cerebellum
become activated in response of motor behavior (Nimmerjahn
et al., 2009). Therefore, severe Purkinje and Bergmann glial cell
loss, fragmentation of astroglia and BGF processes with reduced
expression of glutamate transporter on astroglia and Bergmann
glia might be affecting the interception between the cerebellar
cells resulting in motor deficits following diabetes. To the best of
our knowledge, this is the first study elucidating the influence of
glial activation, cellular degeneration and glutamate toxicity on
altered behavioral activity following STZ-induced diabetes in rats.
The present collective evidence grounds the consideration that
diabetes induces (a) cellular degeneration, (b) glial activation
and (c) and reduced glutamate transportation in the cerebellum.
Later, the triangular associative interplay between these three fac-
tors in cerebellum results in motor deficits following diabetes
(Figure 12). Although Western blot would have been an added
advantage, with the data exclusively derived from the histology,
immunohistochemistry and cellular quantifications, we conclude
that the possible acute involvement of glial cells and associated
neurochemical changes in cerebellum following diabetes offers an
upcoming therapeutic approach for developing the treatment of
diabetes associated motor behavior deficits.
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